Blank, since the conferences are both on the same day, it sure would be worth a lengthy discussion with the analysts to discuss the filing in Dec as opposed to January. It sure makes sense!
Shift change has occurred, Stupid is now in for Newage!! Double time will pile up for this week's holiday!!
2 x $0.25 = $0.50 cents per post. I guess Novartis thinks it is good money well spent!
Shift change is almost here Newage. Don't forget to give thanks to Terry, as he will owe double pay for the next shift. Oh wait, I forgot. He is away, and not paying attention to this stock. You might have to work a double shift.
Short is nothing but Brad of a different stripe. He's just like an absentee Landlord. He's collecting the rent, but doesn't really care how his property looks. He's gonna milk the rent (pay checks, in this case) as everything falls down around it. Sooner or later, somebody pays to fix up the place, or sell it cheap to get out of it. Short's a Loser in the CEO dept., but a Winner in the his wallet dept. The BOD are also collecting their pay and options without much oversight of the company.
I he#$%$rd the technic#$%$l glitch th#$%$t Y#$%$hoo experienced w#$%$s due to #$%$ mess#$%$ge bo#$%$rd poster th#$%$t h#$%$d multiple IDs who overwhelmed their system on m#$%$ny different stocks. App#$%$rently, the poster w#$%$s up 193% on e#$%$ch stock this ye#$%$r, which shocked their whole system. Everybody w#$%$s em#$%$iling Y#$%$hoo to see where they could get this mess#$%$ge bo#$%$rd poster's investment newsletter where he w#$%$s never wrong!!
When a Liar named Terry says "I have stated nothing but Facts", the question is: Who would believe him?
And would you take advice from person who presents no facts, distorts the truth, and repeats himself to boost his ego??
Blue. Too bad you don't short the stock like the infamous Terry, You could have made about 10% from yesterday"s high. They did a nice walk down the last two days. I suppose next week it will go up.
It's always fun to read Terry's response to Iplex. You can tell that's his "hot" button. Just curious Terry, Does Novartis pay you more money for your responses on Iplex, or is that just a "personal" issue?? We know you love Novartis for the CF indication, because that's how you supplement your lemonade stand earnings.
Are you still up 182%, or has it gone up or down the last couple of months?
Bo. Good post. There's no way Terry is an engineer today. He might have been, but he's way too arrogant, even for an engineer. And he ain't that smart, so there's no way he could have continued working in that field. A self righteous engineer or message board poster can't conceive he could be wrong!! Therefore, he has an agenda which is clearly demonstrated every time he posts.
lol, you don't have any idea if the only interest in iPLEX has been for ROP. You said yourself that in 2009 the FDA requested a phase II for ALS, but at that time the company was negotiating to purchase Transave and Arikayce, but I guarantee you that Shire knows that Insmed was given an invitation from the FDA to run a phase II on a disease that has become a "Holy Grail" of orphan disease.....and Shire is all about orphan disease.... I still don't understand how someone who claims to be an engineer doesn't understand that a large part of the cost equation to manufacture the drug would be fixed.... unless you are the kind of engineer that runs a train.... choo choo
Based on what was in the 10Q, it appears Terry and his IDs are wrong that Iplex is "dead". I wonder what companies would be good licensing partners?
Listened to the call's first questioner, Matt Rodin of UBS, and he asked about the Phase 3 trial design and the difference between the Phase 2 and Phase 3 design (about the 15:00 mark). He asked Will Lewis how data from Phase 2 would have done with the new Phase 3 endpoints. Lewis stated that Phase 2 data would have met the Phase 3 endpoints set up for the Trial Design. What was interesting was the fact that Lewis said the Phase 3 Trial endpoints are the same ones used in Tuberculosis trial developments. Why would Insmed do that?
You are real cute with your phony IDs. I'm sure your engineering professors thought the same of you,especially with the fine work you do for Novartis these days!!
Hey Terry. Does Novartis pay good? Why don't you just admit it. You might get more credibility with your other phony IDs.